1.0 2016-05-22 04:30:11 UTC 2026-08-20 03:54:07 UTC Bortezomib SmallMolecule Bortezomib (C19H25BN4O4) is a compound with an average molecular weight of 384.24 g/mol. Bortezomib belongs to the amino acids, peptides, and analogues, a subclass of carboxylic acids and derivatives within the organic compounds. Biologically, it functions as a proteasome inhibitor (PMC10351539, PMC11698957, PMC9323819, PMC9687107). Its recorded protein targets include Proteasome subunit beta type-1 (PSMB1), Proteasome subunit beta type-5 (PSMB5), and Serine protease 1 (PRSS1). The compound is found in healthcare, pharmaceuticals & veterinary products as an antineoplastic agent, as well as in household cleaning & consumer products (pipe accessories, non electric simulated smoking devices) and electrical & electronic equipment (electric hearing aids, radio transmission systems, antennas). Recorded exposure routes include intravenous, parenteral, subcutaneous, intratendinous, and intracavernous. Bortezomib is used as a treatment for cancer (PMC10351539), melanoma (PMC7226512), lymphoma (PMC7532106, PMC9323819), multiple myeloma (PMC3983165, PMC5030385, PMC5053712, PMC6223128, PMC7115922, PMC9387011), renal failure (PMC7109734), and acute renal failure (PMC3227886). It has therapeutic effects on atherosclerosis (PMC12947462) and multiple myeloma (PMC4352933, PMC5916964, PMC6223128, PMC9387011). Associated health effects include nausea, vomiting, fatigue, rash, and itching (PMC10351539), as well as neutropenia and diarrhea (PMC7873303). Other reported effects include thrombosis, hypertension (PMC12946163), congestive heart failure (PMC12946163, PMC5679835), and neuropathic pain (PMC4559079). It is linked to neuropathy (PMC6223128, PMC9387011) and an increase in neuropathy (PMC4382664, PMC7214419, PMC7873303). Additionally, it is associated with thrombocytopenia (PMC10039009, PMC10351539, PMC11795829, PMC7873303) and an increase in thrombocytopenia (PMC4753325). Human Neurotoxin C19H25BN4O4 384.237 384.196885774 [(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido]butyl]boronic acid bortezomib 179324-69-7 CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 GXJABQQUPOEUTA-RDJZCZTQSA-N Organic compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Phenylalanine and derivatives 2-heteroaryl carboxamides Alpha amino acid amides Amphetamines and derivatives Azacyclic compounds Boronic acids Carbonyl compounds Fatty amides Heteroaromatic compounds Hydrocarbon derivatives Monoalkylboranes N-acyl-alpha amino acids and derivatives Organic metalloid salts Organic oxides Organonitrogen compounds Organopnictogen compounds Pyrazinecarboxamides Secondary carboxylic acid amides 2-heteroaryl carboxamide Alkylborane Alpha-amino acid amide Amphetamine or derivatives Aromatic heteromonocyclic compound Azacycle Benzenoid Boronic acid Boronic acid derivative Carbonyl group Carboxamide group Fatty acyl Fatty amide Heteroaromatic compound Hydrocarbon derivative Monoalkylborane Monocyclic benzene moiety N-acyl-alpha amino acid or derivatives Organic metalloid salt Organic nitrogen compound Organic oxide Organic oxygen compound Organic salt Organoboron compound Organoheterocyclic compound Organonitrogen compound Organooxygen compound Organopnictogen compound Phenylalanine or derivatives Pyrazine Pyrazine carboxylic acid or derivatives Pyrazinecarboxamide Secondary carboxylic acid amide Aromatic heteromonocyclic compounds L-phenylalanine derivative amino acid amide pyrazines Detected and Not Quantified Bortezomib Drug Metabolism Action Pathway SMP0142651 logp 1.53 logp 0.89 ALOGPS logs -3.86 ALOGPS solubility 5.32e-02 g/l ALOGPS logp 1.53 ChemAxon pka_strongest_acidic 13.04 ChemAxon pka_strongest_basic -0.7 ChemAxon iupac [(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido]butyl]boronic acid ChemAxon average_mass 384.237 ChemAxon mono_mass 384.196885774 ChemAxon smiles CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O ChemAxon formula C19H25BN4O4 ChemAxon inchi InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 ChemAxon inchikey GXJABQQUPOEUTA-RDJZCZTQSA-N ChemAxon polar_surface_area 124.44 ChemAxon refractivity 99.37 ChemAxon polarizability 40.48 ChemAxon rotatable_bond_count 9 ChemAxon acceptor_count 6 ChemAxon donor_count 4 ChemAxon physiological_charge 0 ChemAxon formal_charge 0 ChemAxon #<HealthEffect::ActiveRecord_Associations_CollectionProxy:0x00007f723c4bbeb8> DB00188 387447 343402 BE0002348 BE0002347 BE0001739